For every 71 people who exercise, one heart attack doesn’t happen
A review of 26,886 patients found cardiac rehab prevents heart attacks and likely cuts deaths, no drug required.
By The Weekend · · 4 min read
Exercise-based cardiac rehabilitation prevents one heart attack for every 71 people with coronary heart disease who do it, and one death for every 125. Those numbers come from a Cochrane review of 107 trials covering 26,886 people — the kind of dataset that turns "exercise is good for you" from a slogan into a dosage.
The person this changes is already out of the hospital, not in it
Picture someone six weeks past a heart attack or a bypass, cleared to go home, told to "take it easy" and largely left to interpret that themselves. Cardiac rehabilitation is the structured version of what happens next: supervised aerobic exercise — static cycling, walking, circuit training — sometimes paired with education or psychological support, delivered in a hospital, a community center, or increasingly a living room via an app. The review found 27 of the 107 trials tested home-based or digital delivery, meaning the effect doesn't require a facility with a defibrillator on the wall. It requires showing up, roughly three times a week, for six to twelve months.
That distinction matters because coronary heart disease is not a single event you recover from — it's a narrowed-artery condition you manage for decades. The people in these trials had survived a heart attack, had bypass surgery, had angioplasty, or lived with angina. Most studies followed them for up to a year, tracking not just whether they survived but whether they went back to the hospital, had another heart attack, or needed another procedure.
Fifty years of the same finding, with better data each decade
Cardiac rehabilitation isn't new. The idea that structured exercise helps heart patients rather than harms them dates to the 1960s and 1970s, when the standard advice for a heart attack survivor was extended bed rest — sometimes six weeks of it — on the theory that exertion would trigger another event. Early trials in that era began testing the opposite premise and found lower mortality among patients who exercised. Cochrane has been updating this specific review since 2001, each version adding trials as the evidence base widened.
What's changed most recently isn't the conclusion — it's who's in the room. Women made up only 17% of participants across all 107 studies, a gap that has persisted through five decades of cardiac research despite heart disease being the leading cause of death worldwide for both sexes. The newer trials in this update include more women, more countries outside North America and Western Europe, and more remote delivery models, suggesting the treatment is finally catching up to who actually has the disease — even if the participant math hasn't caught up yet.
The benefit that doesn't show up: fewer stents, fewer bypasses
Here is the catch nobody selling cardiac rehab programs tends to lead with: exercise makes little to no difference to whether a patient eventually needs a stent or bypass surgery. It reduces heart attacks by a wide margin — 25 trials, 8,584 people, a large effect. It probably reduces hospital admissions overall, one prevented for every 17 participants. It probably reduces death from any cause and may reduce heart-related death. But the plumbing itself — the blocked or narrowed vessel that got you into rehab in the first place — doesn't get less blocked because you cycled three times a week. Exercise changes what happens around the blockage: less inflammation, better vascular function, lower risk of a clot forming. It does not reverse the anatomy. Anyone hoping rehab is an alternative to a procedure they've been told they need is reading the wrong study.
The other quiet fact: this is not a drug, and nobody is funding a marketing campaign for it the way they would a hepatitis injection or a new cholesterol pill. Cochrane's review notes the intervention "appears to be cost-effective," language notably more hedged than the mortality numbers, because cost-effectiveness studies are harder to standardize across 107 trials run in different health systems with different rehab costs and different definitions of a prevented hospital stay. The mortality benefit is measured with real confidence. The cost claim is closer to a reasonable inference.
The open question is why so few patients actually enroll
The evidence for cardiac rehabilitation has been strong enough to sit in international treatment guidelines for years. The honest gap isn't in the data — it's in uptake. Referral and completion rates for cardiac rehab programs have historically run low across health systems, often because patients live far from a center, can't take time off work for a 12-week program, or simply aren't referred by the discharging physician in the first place. The digital and home-based trials in this review exist partly as an answer to that problem, but the review itself doesn't measure how many eligible patients actually get offered rehab versus how many complete it once offered. That's the number this dataset can't give you, and it's arguably the more consequential one: a treatment that prevents one heart attack in 71 people is only as good as the fraction of eligible patients who ever start it.
Does cardiac rehab work if you do it at home instead of a clinic?
The review included 27 home-based or digital trials and found benefits consistent with clinic-based programs, though most evidence still comes from supervised settings.
How long do the well-being benefits last?
Improved well-being was tracked for up to 12 months in these trials — the review doesn't establish whether gains persist beyond that window.